Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners

All the sessions from Transform 2021 are available on-demand now. Watch now. Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in the Company’s drug development pipeline Strengthens its Board of Directors with the addition of John de Koning of LSP, […]